WuXi Biologics Ranked Top 1% Globally in S&P Sustainability Yearbook for Fourth Consecutive Year

WuXi Biologics has been ranked first in its industry and placed in the Top 1% globally in the S&P Global Sustainability Yearbook 2026, following strong performance in the 2025 Corporate Sustainability Assessment (CSA).

The recognition marks the fourth consecutive year that the global Contract Research, Development and Manufacturing Organization (CRDMO) has achieved this highest distinction. The Yearbook identifies companies demonstrating leading environmental, social and governance (ESG) performance within their industries and highlights organisations that have embedded sustainability into core business strategy and operational decision-making.

More than 9,200 companies were assessed in the 2025 CSA, with only 848 across 59 industries selected for inclusion in the 2026 Yearbook. WuXi Biologics’ continued Top 1% placement indicates sustained leadership relative to peers in the Life Sciences Tools & Services sector and signals consistent performance across successive assessment cycles.

The ranking reflects performance across environmental management, governance oversight, transparency and sustainability integration within global operations. Achieving this position over multiple years suggests that ESG principles are deeply embedded in corporate systems rather than driven by short-term initiatives.

Build the future you deserve. Get started with our top-tier Online courses: ACCA, HESI A2, ATI TEAS 7, HESI EXIT, NCLEX-RN, NCLEX-PN, and Financial Literacy. Let Serrari Ed guide your path to success. Enroll today.

Recognition Reflects Consistent ESG Performance

WuXi Biologics’ continued inclusion at the Top 1% level reflects sustained ESG integration across governance, environmental management and operational practices. The company has positioned sustainability as a central pillar of its global biologics platform, integrating ESG considerations across manufacturing, supply chain and corporate governance.

Dr. Chris Chen, CEO of WuXi Biologics and chairman of the ESG Committee, said the ranking demonstrates the company’s long-term commitment to strengthening sustainability performance across its global operations and partnerships.

“Our strong performance in S&P Global’s latest CSA and our inclusion in the Yearbook for the fourth consecutive year reflect WuXi Biologics’ steadfast commitment to continuously enhancing our sustainability performance,” Chen said.

The company positions sustainability as a core component of its Green CRDMO strategy, aligning biologics discovery, development and manufacturing with ESG objectives across the value chain. This integration is intended to support responsible growth while maintaining operational efficiency, innovation capacity and environmental stewardship.

Multi-year recognition also suggests that ESG performance has become embedded in corporate governance and operating systems rather than treated as a standalone initiative. Such consistency is increasingly viewed by stakeholders as an indicator of organisational maturity in sustainability management.

Sustainability Yearbook Recognises Industry Leaders

The S&P Global Sustainability Yearbook highlights companies with the strongest CSA results within each industry classification. Inclusion indicates performance among the top ESG performers relative to sector peers and signals strong sustainability management practices across material ESG factors.

The CSA evaluates companies across environmental, social and governance criteria, assessing how organisations manage sustainability risks, opportunities and impacts through policies, operational controls, performance metrics and disclosure practices. The assessment also examines how companies integrate ESG considerations into strategy and decision-making processes.

Companies are assessed using specific CSA questionnaires and methodology, ensuring that performance is measured against relevant sustainability factors for each sector. WuXi Biologics’ Top 1% designation therefore represents leadership within the global life sciences tools and services industry rather than across all sectors.

The Yearbook is widely used by investors and stakeholders as a reference point for ESG performance comparison across industries. Inclusion may influence investor perception, partner confidence and stakeholder trust in sustainability practices.

Strong Performance Across Global ESG Frameworks

WuXi Biologics has received multiple ESG recognitions across global rating systems and sustainability indices, reinforcing its consistent sustainability performance across different assessment methodologies and geographic markets.

The company holds:

• MSCI AAA rating
• EcoVadis Platinum Medal
• Inclusion in Dow Jones Sustainability Indices
• Inclusion in FTSE4Good Index Series
• Inclusion in Hang Seng ESG 50 Index
• Prime rating from ISS ESG
• CDP “A List” for Climate Change, Water Security and Supplier Engagement
• Sustainalytics negligible-risk rating
• Sustainalytics ESG top-rated company (five consecutive years)

These recognitions reflect performance across environmental management, governance standards, transparency and risk oversight. Independent ESG ratings provide external validation of sustainability practices and support investor confidence in ESG performance consistency over time.

The breadth of recognition across multiple frameworks indicates alignment with global sustainability expectations across markets and regulatory environments. It also demonstrates the company’s ability to meet diverse ESG evaluation standards applied by investors, rating agencies and sustainability benchmarks worldwide.

Global CRDMO Platform with ESG Integration

WuXi Biologics provides end-to-end biologics discovery, development and manufacturing services from concept through commercialisation. Operations span China, the United States, Ireland, Germany, Singapore and Qatar, with more than 12,000 employees globally.

As of 31 December 2025, the company supported 945 integrated client projects, including:

• 74 Phase III projects
• 25 commercial manufacturing projects

This global platform enables pharmaceutical and biotechnology partners to advance biologics therapies from research through clinical development to commercial production.

WuXi Biologics states that ESG responsibilities are integrated into its business model and long-term strategy, supporting sustainable growth across its operations. Sustainability considerations are embedded across facility design, manufacturing processes and supply-chain management, ensuring that environmental and governance factors are considered alongside scientific and operational priorities.

The company’s approach aims to align biologics innovation and production with environmental stewardship and responsible business practices. Integrating ESG into a global CRDMO platform also supports consistent standards across multiple jurisdictions and regulatory environments.

One decision can change your entire career. Take that step with our Online courses in ACCA, HESI A2, ATI TEAS 7, HESI EXIT, NCLEX-RN, NCLEX-PN, and Financial Literacy. Join Serrari Ed and start building your brighter future today.

Sustainable Manufacturing and Clean-Energy Facilities

WuXi Biologics applies next-generation biomanufacturing technologies and clean-energy sources across production facilities to improve resource efficiency and reduce environmental impact.

Advanced manufacturing technologies support reduced material consumption, improved energy efficiency and enhanced production yields. Clean-energy integration contributes to lower emissions intensity across operations and supports the company’s broader environmental objectives.

Environmental management is incorporated into facility design, production processes and operational monitoring systems. These measures support the company’s positioning as a Green CRDMO focused on sustainable biologics manufacturing and environmentally responsible production practices.

Sustainable production practices are increasingly relevant in pharmaceutical supply chains, where environmental footprint, energy use and resource efficiency are becoming key considerations for partners, regulators and stakeholders. Manufacturers demonstrating environmental performance may strengthen their position in global biologics outsourcing markets.

ESG Governance Led by Executive Management

The company has established an ESG Committee led by the CEO to oversee sustainability strategy and implementation across global operations.

Executive-level oversight integrates ESG considerations into corporate governance, risk management and decision-making processes. Sustainability priorities are therefore aligned with business strategy, capital allocation and operational planning rather than managed separately.

Leadership involvement supports accountability, performance monitoring and continuous improvement across environmental, social and governance objectives. It also strengthens transparency and consistency in ESG implementation across facilities and regions, ensuring that sustainability practices are applied uniformly across the global organisation.

This governance structure reflects an approach in which sustainability is managed at strategic level rather than through isolated initiatives. Executive engagement is increasingly regarded as a key factor in effective ESG integration within multinational corporations.

CSA Score Indicates Sector Leadership

WuXi Biologics achieved a CSA score of 86 in the Life Sciences Tools & Services industry category.

The S&P Global ESG Score measures performance on material ESG risks, opportunities and impacts relative to industry peers. Scores are derived from company disclosures, stakeholder analysis and modelling through the CSA process.

The methodology applies a double-materiality approach, assessing both environmental or societal impact and financial implications for corporate value creation. ESG scores are comparable only within industry classifications rather than across sectors, ensuring relevance to sector-specific sustainability challenges.

WuXi Biologics’ Top 1% ranking indicates performance above most companies in its sector across governance, environmental management and sustainability integration dimensions. Sustained high scoring across assessment cycles signals consistency in ESG management practices and disclosure quality.

Sustainability as Competitive Factor in Biologics Manufacturing

Sustainability expectations are increasing across pharmaceutical and biologics supply chains, particularly in manufacturing practices, environmental footprint and governance standards. Regulatory scrutiny, investor expectations and partner requirements are driving greater emphasis on ESG performance within life sciences manufacturing.

WuXi Biologics integrates ESG principles into operations, technology deployment and production systems, positioning sustainability as part of its operating model rather than a standalone initiative. Environmental efficiency, governance oversight and responsible manufacturing practices are becoming key differentiators in biologics production partnerships.

Recognition across multiple ESG frameworks may strengthen trust among pharmaceutical and biotechnology partners seeking sustainable development and manufacturing solutions. ESG performance is increasingly considered in partner selection, regulatory evaluation and supply-chain decisions, particularly for global pharmaceutical companies with sustainability commitments.

Sustained ESG leadership therefore supports competitive positioning within the global CRDMO market and may enhance the company’s attractiveness as a long-term manufacturing partner.

ESG Integration Across the Biologics Value Chain

WuXi Biologics states that sustainability integration supports responsible practices throughout the biologics value chain, from research and development to manufacturing and delivery.

The company participates in:

• United Nations Global Compact (UNGC)
• Pharmaceutical Supply Chain Initiative (PSCI)

These frameworks promote responsible environmental, social and governance practices across global pharmaceutical and biotechnology supply chains. Participation reflects alignment with international sustainability principles and industry standards governing responsible production and supply-chain management.

WuXi Biologics aims to enable partners to meet ESG commitments while advancing biologics innovation and manufacturing. Value-chain sustainability integration supports responsible sourcing, production and collaboration across the biologics ecosystem, reinforcing shared sustainability objectives between manufacturers and pharmaceutical developers.

Outlook

WuXi Biologics’ continued Top 1% ranking in the S&P Global Sustainability Yearbook indicates sustained ESG leadership within the biologics manufacturing sector. Sustainability performance is increasingly linked to regulatory expectations, supply-chain standards and partner selection in pharmaceutical industries.

Multi-year recognition suggests ESG integration is embedded within the company’s operating model and governance structures rather than treated as a temporary initiative. For partners and investors, this supports confidence in environmental management, governance oversight and responsible manufacturing practices across global operations.

As sustainability requirements expand across life sciences sectors, ESG differentiation is likely to remain a competitive factor in biologics manufacturing. Pharmaceutical companies and biotechnology developers are placing greater emphasis on environmental footprint, supply-chain transparency and governance alignment when selecting manufacturing partners.

Companies demonstrating consistent sustainability performance may be better positioned to meet evolving regulatory and stakeholder expectations. ESG leadership can also support long-term operational resilience, risk management and reputational strength within global pharmaceutical supply chains.

WuXi Biologics’ continued inclusion in leading ESG indices and assessments indicates that sustainability remains central to its global biologics platform and strategic direction. Sustained performance across environmental, social and governance dimensions suggests that ESG integration is likely to remain a defining characteristic of the company’s growth and positioning within the CRDMO sector.

Ready to take your career to the next level? Join our Online courses: ACCA, HESI A2, ATI TEAS 7 , HESI EXIT  , NCLEX – RN and NCLEX – PN, Financial Literacy!🌟 Dive into a world of opportunities and empower yourself for success. Explore more at Serrari Ed and start your exciting journey today! ✨

Track GDP, Inflation and Central Bank rates for top African markets with Serrari’s comparator tool.

See today’s Treasury bonds and Money market funds movement across financial service providers in Kenya, using Serrari’s comparator tools.

photo source: Google

By: Rosemary Wambui

3rd March 2026